Kingsoft Cloud Holdings Limited vs Vaxcyte Inc. Common Stock — how do they compare? Kingsoft Cloud Holdings Limited trades at $8.6 (market cap $2.77B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 3.8× Kingsoft Cloud Holdings Limited's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| KC | PCVX | |
|---|---|---|
Market Cap | $2.77B | $10.51B |
Volume | 986,009 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $18.21 | $73.82 |
52-Week Low | $8.58 | $40.32 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $3.10B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $9.32, up 0.76% with a bearish technical signal despite recent earnings beats. The company shows improving revenue trends ($11.0B projected for 2026) and significant AI cloud growth, though profitability remains negative with -5.46% net margin. Analyst sentiment is strongly positive with 70% buy ratings and 60.25% upside potential cited.
KC presents a high-risk, high-reward opportunity with strong AI-driven growth potential but persistent profitability challenges. The stock's appeal hinges on continued AI cloud expansion and margin improvement, though investors face execution risks and Chinese regulatory exposure. Wall Street optimism contrasts with current technical weakness.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →